Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC

被引：1
|
作者：
El-Ghazzi, Nathan [1 ]
Lavaud, Pernelle [2 ]
机构：
[1] Univ Clermont Auvergne, Med Oncol Serv, Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy Canc Campus, Villejuif, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 03期
关键词：
Non-small-cell lung carcinoma; Immunotherapy; Checkpoint immune inhibitors; Chemotherapy; PLATINUM-DOUBLET CHEMOTHERAPY; PLUS IPILIMUMAB;
D O I：
10.1016/j.bulcan.2021.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 233
页数：4
相关论文
共 50 条
  • [31] First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
    Gettinger, Scott
    Rizvi, Naiyer
    Chow, Laura
    Borghaei, Hossein
    Brahmer, Julie
    Shepherd, Frances
    Ready, Neal
    Gerber, David
    Antonia, Scott
    Goldman, Jonathan W.
    Juergens, Rosalyn
    Geese, William
    Young, Tina
    L, Xuemei, I
    Hellmann, Matthew
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S250 - S251
  • [32] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE
    Diamantogiannis, F.
    Viktoratos, P.
    May, J.
    Malcolm, B.
    Van de Wetering, G.
    Ignacio, T.
    VALUE IN HEALTH, 2019, 22 : S468 - S469
  • [33] Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.
    Mehmi, Inderjit
    Hamid, Omid
    Hodi, F. Stephen
    Vassalo, Melinda
    Malatyali, Saundra
    Krishnarajapet, Swathi
    O'Donnell, Nan
    Castrence, Angeli
    Lim, Eunice
    Gormley, Jill
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
    Diab, Adi
    Tykodi, Scott S.
    Daniels, Gregory A.
    Maio, Michele
    Curti, Brendan D.
    Lewis, Karl D.
    Jang, Sekwon
    Kalinka, Ewa
    Puzanov, Igor
    Spira, Alexander, I
    Cho, Daniel C.
    Guan, Shanhong
    Puente, Erika
    Tuan Nguyen
    Hoch, Ute
    Currie, Sue L.
    Lin, Wei
    Tagliaferri, Mary A.
    Zalevsky, Jonathan
    Sznol, Mario
    Hurwitz, Michael E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2914 - +
  • [35] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN
    Baker, T. M.
    Paly, V. F.
    Thybo, S.
    Hultberg, M.
    Minacori, R.
    Kotapati, S.
    Sabater, J.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A731
  • [36] Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Schenker, Michael
    Zurawski, Bogdan
    Kim, Sang-We
    Mahave, Mauricio
    Alexandru, Aurelia
    Peters, Solange
    Pluzanski, Adam
    Caro, Reyes Bernabe
    Linardou, Helena
    Burgers, Jacobus A.
    Nishio, Makoto
    Martinez-Marti, Alex
    Azuma, Koichi
    Axelrod, Rita
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    Li, Li
    Bushong, Judith
    Gupta, Ravi G.
    Grootendorst, Diederik J.
    Eccles, Laura J.
    Brahmer, Julie R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1055 - 1069
  • [37] Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
    Moura, Bianca Gautron
    Gerard, Camille L.
    Testart, Nathalie
    Caikovski, Marian
    Wicky, Alexandre
    Aedo-Lopez, Veronica
    Berthod, Gregoire
    Homicsko, Krisztian
    Prior, John O.
    Dromain, Clarisse
    Kandalaft, Lana E.
    Cuendet, Michel A.
    Michielin, Olivier
    CANCERS, 2023, 15 (01)
  • [38] Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA"
    Paz-Ares, Luis G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : E102 - E103
  • [39] Efficacy of first-line (1L) nivolumab (N) plus ipilimumab (I) by tumor histologic subtype in patients ( pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)
    Borghaei, H.
    Balli, D.
    Paz-Ares, L.
    Reck, M.
    Ramalingam, S. S.
    Brahmer, J. R.
    Ciuleanu, T-E.
    Pluzanski, A.
    Lee, J-S.
    Gainor, J.
    Schenker, M.
    Schoenfeld, A.
    Caro, R. Bernabe
    Ready, N.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Baxi, V.
    Geese, W.
    O'Byrne, K. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S64 - S65
  • [40] Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy
    Nagpal, Ria
    Campione, Marina
    Rebuzzi, Sara Elena
    Fratino, Lucia
    Rescigno, Pasquale
    Bracarda, Sergio
    Bimbatti, Davide
    De Giorgi, Ugo
    Santoni, Matteo
    Calabro, Fabio
    Rizzo, Mimma
    Signori, Alessio
    Giannarelli, Diana
    Fornarini, Giuseppe
    Basso, Umberto
    Banna, Giuseppe Luigi
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2025, 24
12345